Denna webbsida är endast avsedd för läkare och sjukvårdspersonal med förskrivningsrätt.

Current treatment and recent therapeutic developments in TNBC

We are delighted to invite you to a webinar exploring the evolving treatment landscape of metastatic triple negative breast cancer (mTNBC). Dr Mark Harries, Consultant Medical Oncologist at Guy’s and St Thomas’ in London will discuss the current and evolving treatment landscape of TNBC and introducing the newly approved antibody-drug conjugate (ADC), the first-in-class ADC that targets TROP-2, a commonly expressed marker in TNBC.

October 5, 2022 | 12:15 – 12:55 (CEST) SE-TRO-0060

For more information and registration click here

Liknande poster

Caring for patients with metastatic TNBC: The nurse’s perspective

The treatment landscape of locally advanced upper gastrointestinal cancer

mCRPC – treatment options, different patient needs: where does targeted alpha treatment fit in?